Clinical Trial: 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Open Label Trial Of 3,4-Diaminopyridine In Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS)
Brief Summary: The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).
Detailed Summary:
Sponsor: Lahey Clinic
Current Primary Outcome: Increase in strength and autonomic symptoms [ Time Frame: 1-10 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Lahey Clinic
Dates:
Date Received: March 30, 2009
Date Started: June 2001
Date Completion: June 2020
Last Updated: June 22, 2016
Last Verified: June 2016